近99%收入依赖单一产品，这家中医药公司也要赴港上市！

Core Viewpoint - The article highlights the accelerating trend of Traditional Chinese Medicine (TCM) companies pursuing IPOs on the Hong Kong Stock Exchange, with a notable example being Shandong Hanfang Pharmaceutical Co., Ltd. which submitted its prospectus in February 2026 [1][5]. Group 1: Company Overview - Hanfang Pharmaceutical, established in June 2004, focuses on the production, sales, and research of TCM products, particularly in the treatment of skin and mucosal diseases [4]. - The company is a family-controlled entity, with the chairman holding 90% of the shares and the general manager holding 10% [5]. Group 2: Financial Performance - The total revenue for Hanfang Pharmaceutical was reported as 1.053 billion yuan in 2023, 992 million yuan in 2024, and 803 million yuan for the first nine months of 2025. Net profits were 237 million yuan, 199 million yuan, and 145 million yuan for the same periods respectively [5]. - The gross profit margin has consistently remained above 80%, with a gross profit of 677 million yuan and a gross margin of 84.3% for the first nine months of 2025 [5]. Group 3: Product Contribution - The flagship product, "Fangfang Huangbai Liquid," is a prescription topical TCM used for treating skin and mucosal diseases, contributing to nearly all of the company's revenue, with 99.8%, 99.8%, and 99.7% of total revenue from this product in 2023, 2024, and the first nine months of 2025 respectively [6][7]. - This product ranks fourth in the Chinese topical TCM market, holding a 1.1% market share [7]. Group 4: Competitive Advantage - "Fangfang Huangbai Liquid" is the only approved prescription topical TCM in China and is classified as a national second-level protected TCM variety, granting it exclusive market protection [8]. Group 5: Future Strategies - Despite strong competitive barriers, the company faces potential risks, including a slight revenue decline from 1.053 billion yuan in 2023 to 992 million yuan in 2024, and a decrease in net profit margin from approximately 22.5% to 20% [10]. - The company plans to diversify its product portfolio through three core strategies: developing new TCM products, converting clinically validated formulations into innovative TCM, and commercializing acquired classic TCM formulations [13].